128 related articles for article (PubMed ID: 36167277)
1. Urotensin receptor acts as a novel target for ameliorating fasting-induced skeletal muscle atrophy.
Yin L; Li N; Jia W; Wang N; Liang M; Shang J; Qiang G; Du G; Yang X
Pharmacol Res; 2022 Nov; 185():106468. PubMed ID: 36167277
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
[TBL] [Abstract][Full Text] [Related]
3. Urotensin II Induces Mice Skeletal Muscle Atrophy Associated with Enhanced Autophagy and Inhibited Irisin Precursor (Fibronectin Type III Domain Containing 5) Expression in Chronic Renal Failure.
Pan YJ; Zhou SJ; Feng J; Bai Q; A LT; Zhang AH
Kidney Blood Press Res; 2019; 44(4):479-495. PubMed ID: 31238319
[TBL] [Abstract][Full Text] [Related]
4. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.
Papadopoulos P; Bousette N; Al-Ramli W; You Z; Behm DJ; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
Atherosclerosis; 2009 Jun; 204(2):395-404. PubMed ID: 19111831
[TBL] [Abstract][Full Text] [Related]
5. The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions.
Ugan RA; Cadirci E; Halici Z; Toktay E; Cinar I
Eur J Pharmacol; 2018 Jan; 818():457-469. PubMed ID: 29133126
[TBL] [Abstract][Full Text] [Related]
6. Role of urotensin II and its receptor in health and disease.
McDonald J; Batuwangala M; Lambert DG
J Anesth; 2007; 21(3):378-89. PubMed ID: 17680191
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.
Elshourbagy NA; Douglas SA; Shabon U; Harrison S; Duddy G; Sechler JL; Ao Z; Maleeff BE; Naselsky D; Disa J; Aiyar NV
Br J Pharmacol; 2002 May; 136(1):9-22. PubMed ID: 11976263
[TBL] [Abstract][Full Text] [Related]
8. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
[TBL] [Abstract][Full Text] [Related]
9. Towards Targeting the Urotensinergic System: Overview and Challenges.
Nassour H; Iddir M; Chatenet D
Trends Pharmacol Sci; 2019 Oct; 40(10):725-734. PubMed ID: 31500846
[TBL] [Abstract][Full Text] [Related]
10. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
[TBL] [Abstract][Full Text] [Related]
11. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
12. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
[TBL] [Abstract][Full Text] [Related]
13. Development of Novel
Poret B; Desrues L; Bonin MA; Pédard M; Dubois M; Leduc R; Modzelewski R; Decazes P; Morin F; Vera P; Castel H; Bohn P; Gandolfo P
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204509
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse.
Wang HX; Zeng XJ; Liu Y; Wang J; Lu LQ; Hao G; Zhang LK; Tang CS
Regul Pept; 2009 Apr; 154(1-3):85-90. PubMed ID: 19323985
[TBL] [Abstract][Full Text] [Related]
15. Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction.
Dubessy C; Cartier D; Lectez B; Bucharles C; Chartrel N; Montero-Hadjadje M; Bizet P; Chatenet D; Tostivint H; Scalbert E; Leprince J; Vaudry H; Jégou S; Lihrmann I
J Neurochem; 2008 Oct; 107(2):361-74. PubMed ID: 18710417
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas.
Morales MG; Abrigo J; Acuña MJ; Santos RA; Bader M; Brandan E; Simon F; Olguin H; Cabrera D; Cabello-Verrugio C
Dis Model Mech; 2016 Apr; 9(4):441-9. PubMed ID: 26851244
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.
Tandon R; Soni A; Singh RK; Sodhi R; Seth MK; Sinha S; Sahdev S; Dhage G; Das B; Dastidar SG; Shriumalla RK; Yonesu K; Marumoto S; Nagayama T
Eur J Pharmacol; 2020 Nov; 886():173391. PubMed ID: 32745605
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function.
Maguire JJ; Kuc RE; Kleinz MJ; Davenport AP
Peptides; 2008 May; 29(5):735-42. PubMed ID: 17905478
[TBL] [Abstract][Full Text] [Related]
19. Loss of urotensin II receptor diminishes hyperglycemia and kidney injury in streptozotocin-treated mice.
Peixoto-Neves D; Kanthakumar P; Kumar R; Soni H; Adebiyi A
J Mol Endocrinol; 2022 Apr; 68(3):167-178. PubMed ID: 35244607
[TBL] [Abstract][Full Text] [Related]
20. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.
Johns DG; Ao Z; Naselsky D; Herold CL; Maniscalco K; Sarov-Blat L; Steplewski K; Aiyar N; Douglas SA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Oct; 370(4):238-50. PubMed ID: 15549273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
